Q-omics provides the consensus-scored CLDN22 profile across patient tissues and cancer cell-line models. Additionally, CLDN22 mutation status shows 1,161 significant gene co-expression associations, with the highest sampling consensus in UCEC.

Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.

Premium analyses for CLDN22 — synthetic lethality, tumor antigen, and pembrolizumab response.

View premium →

Cross-omics associations

This table shows molecular features associated with CLDN22 in patient tissues and cancer cell lines. In patient samples, CLDN22 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, CLDN22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.

Associated data type	Strength (# associated data)	Lineage of highest associated data
▼Mutation
RNA	1,161	UCEC (1118)	view →
Protein (RPPA)	16	UCEC (16)	view →
▼RNA
Mutation	17	SCLC (17)	view →
RNA	3	SCLC (3)	view →

Associated data type	Strength (# associated data)	Lineage of highest associated data
▼CRISPR
CRISPR	1,536	BONE (115)	view →
RNA	1,351	URINARY_TRACT (331)	view →
▼RNA
RNA	5,375	BLOOD_Leukemia (1917)	view →
Function (RNA)	2,339	BLOOD_Leukemia (875)	view →
▼Mutation
Mutation	827	BLOOD_Leukemia (664)	view →